MEI Pharma Files 8-K on Shareholder Nominations

TL;DR

MEI Pharma filed an 8-K regarding shareholder nominations, signaling potential board changes.

AI Summary

MEI Pharma, Inc. filed an 8-K on November 25, 2024, reporting on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for the report is November 22, 2024. The company is incorporated in Delaware and its principal executive offices are located in San Diego, California.

Why It Matters

This filing indicates potential changes or activism related to the composition of MEI Pharma's board of directors, which could impact the company's strategic direction.

Risk Assessment

Risk Level: medium — Filings related to shareholder nominations can indicate internal disputes or activist investor involvement, which may lead to uncertainty and strategic shifts.

Key Players & Entities

• MEI Pharma, Inc. (company) — Registrant
• Exchange Act Rule 14a-11 (legal_document) — Subject of filing
• November 22, 2024 (date) — Date of earliest event reported
• November 25, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar

Filing Documents

• meip-20241122.htm (8-K) — 39KB
• 0000950170-24-130593.txt ( ) — 150KB
• meip-20241122.xsd (EX-101.SCH) — 24KB
• meip-20241122_htm.xml (XML) — 5KB

08 Shareholder Director Nominations

Item 5.08 Shareholder Director Nominations On November 22, 2024, MEI Pharma, Inc. (the "Company") announced that the Company's 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") will be held on January 30, 2025. The Company's stockholders of record as of the close of business on December 9, 2024 shall be entitled to notice of and to vote at the 2025 Annual Meeting. The Company has set a deadline, as set forth in the following paragraph, for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), for inclusion in the Company's proxy materials for the 2025 Annual Meeting. Pursuant to the rules of the Securities and Exchange Commission ("SEC"), the Company is providing notice of the deadlines for such proposals by means of this Current Report on Form 8-K. Any stockholder proposal intended to be considered for inclusion in the Company's proxy materials for the 2025 Annual Meeting in accordance with Rule 14a-8 must be delivered to, or mailed and received at, the Company's principal executive offices at 9920 Pacific Heights Blvd., Suite 150, San Diego, California 92121 on or before the close of business on [December 10, 2024], which is the [51st] day prior to January 30, 2025 and which the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials prior to the 2025 Annual Meeting. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company's proxy materials for the 2025 Annual Meeting must also comply with all applicable SEC rules. There is a separate submission period applicable to the submission by stockholders of notice of a director nomination or a stockholder proposal outside of the processes of Rule 14a-8. Under the Company's Sixth Amended and Restated Bylaws, such a nomination or proposal must be received by the Secretary of the Company not l

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI PHARMA, INC. Date: November 25, 2024 By: /s/ Justin J. File Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR